drugset / Trial / NCT01769365

Concomitant, Sequential, and Standard Triple Therapy for H. Pylori Infection

NCT01769365 ↗

Phase 4 Completed 307 enrolled Kaohsiung Veterans General Hospital.
RandomizedParallel-groupOpen-labelTreatment

Summary

To simultaneously compare the efficacies of 7-day triple, 10-day sequential and 7-day quadruple therapies for H. pylori infection in Taiwan. Consecutive H. pylori-infected patients were randomly assigned to a 7-day standard triple therapy (pantoprazole, clarithromycin, and amoxicillin for 7 days), a 10-day sequential therapy (pantoprazole and amoxicillin for 5 days, followed by pantoprazole, clarithromycin and metronidazole for a further 5 days) or a 7-day quadruple therapy (pantoprazole, clarithromycin, amoxicillin and metronidazole for 7 days). The end point is to evaluate the effectiveness of Helicobacter pylori eradication rates between three groups.

Timeline

Start
2010-07
Primary completion
2013-10
Completion
2013-10

Outcome

Met primary endpoint

paper In conclusion, the seven-day concomitant therapy is superior to the 7-day standard triple therapy for H. pylori eradication. PMID 25070099 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Amoxicillin Other / unclassified 1 g —
Subject Clarithromycin Small molecule 500 mg —
Subject Metronidazole Small molecule 500 mg —
Subject Pantoprazole Other / unclassified 40 mg —